Valuation: argenx SE

Capitalization 4.26TCr 4.98TCr 3.95TCr 3.71TCr 6.88TCr 4,56300Cr 7.37TCr 45TCr 18TCr 2,15700Cr 19TCr 18TCr 7,87800Cr P/E ratio 2025 *
46x
P/E ratio 2026 * 27.7x
Enterprise value 3.97TCr 4.64TCr 3.68TCr 3.45TCr 6.41TCr 4,24900Cr 6.86TCr 42TCr 17TCr 2,00800Cr 17TCr 17TCr 7,33500Cr EV / Sales 2025 *
11x
EV / Sales 2026 * 7.59x
Free-Float
99.23%
Yield 2025 *
0.02%
Yield 2026 * 0.04%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.57%
1 week+1.33%
Current month-2.34%
1 month-3.58%
3 months-3.85%
6 months+44.93%
Current year-2.34%
More quotes
1 week 663.2
Extreme 663.2
717.6
1 month 660.4
Extreme 660.4
733.4
Current year 660.4
Extreme 660.4
728
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 9.23
Extreme 9.23
810
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 15/07/2008
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Director/Board Member 54 01/07/2014
Chairman 68 15/10/2008
Director/Board Member 76 13/05/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.57%+1.33%+11.75%+92.84% 4.98TCr
-0.91%-4.69%+77.60%+1.08% 4.22TCr
-4.40%-4.37%+103.67%+648.66% 3.33TCr
+11.78%+8.14%+0.64%-17.36% 2.96TCr
+1.46%-2.60%+114.07%-45.43% 2.04TCr
+0.10%-6.84%+36.57%-22.93% 2.01TCr
-1.40%-8.91%+91.32%+122.57% 1.35TCr
-2.93%-10.63%+161.97% - 1.28TCr
+4.92%-4.53%-23.76%+283.83% 1.3TCr
Average -0.33%-3.52%+63.76%+132.91% 2.61TCr
Weighted average by Cap. -0.55%-2.39%+57.06%+133.98%
See all sector performances

Financials

2025 *2026 *
Net sales 359.62Cr 420.6Cr 333.82Cr 313.08Cr 580.83Cr 39TCr 621.95Cr 3.83TCr 1.52TCr 18TCr 1.58TCr 1.55TCr 67TCr 501.79Cr 586.88Cr 465.8Cr 436.85Cr 810.45Cr 54TCr 867.82Cr 5.35TCr 2.12TCr 25TCr 2.2TCr 2.16TCr 93TCr
Net income 99Cr 115.28Cr 91Cr 86Cr 159.2Cr 11TCr 170.47Cr 1.05TCr 415.54Cr 4.99TCr 432.32Cr 423.47Cr 18TCr 178.77Cr 209.09Cr 165.95Cr 155.64Cr 288.75Cr 19TCr 309.19Cr 1.9TCr 753.68Cr 9.05TCr 784.1Cr 768.06Cr 33TCr
Net Debt -293.46Cr -343.22Cr -272.41Cr -255.48Cr -473.97Cr -31TCr -507.52Cr -3.13TCr -1.24TCr -15TCr -1.29TCr -1.26TCr -54TCr -450.92Cr -527.39Cr -418.58Cr -392.57Cr -728.29Cr -48TCr -779.85Cr -4.8TCr -1.9TCr -23TCr -1.98TCr -1.94TCr -83TCr
More financial data * Estimated data
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
More about the company
Date Price Change Volume
22/26/22 700.00 +0.57% 5,607
21/26/21 696.00 +1.49% 73,271
20/26/20 685.80 +1.84% 70,588
19/26/19 673.40 -2.91% 45,880
16/26/16 693.60 -0.49% 91,571

Real-time Euronext Bruxelles, January 22, 2026 at 04:10 pm IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
696.00EUR
Average target price
824.20EUR
Spread / Average Target
+18.42%
Consensus

Quarterly revenue - Rate of surprise